이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Dechra Pharmaceuticals 관리

관리 기준 확인 4/4

Dechra Pharmaceuticals' CEO는 Ian Page, Nov2001 에 임명되었습니다 의 임기는 22.17 년입니다. 총 연간 보상은 £ 1.04M, 59.9% 로 구성됩니다. 59.9% 급여 및 40.1% 보너스(회사 주식 및 옵션 포함). 는 £ 15.64M 가치에 해당하는 회사 주식의 0.36% 직접 소유합니다. 15.64M. 경영진과 이사회의 평균 재임 기간은 각각 4.8 년과 4.3 년입니다.

주요 정보

Ian Page

최고 경영자

UK£1.0m

총 보상

CEO 급여 비율	59.9%
CEO 임기	22.2yrs
CEO 소유권	0.4%
경영진 평균 재임 기간	4.8yrs
이사회 평균 재임 기간	4.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Ian Page 의 보수는 Dechra Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2023	UK£1m	UK£621k	-UK£28m
Mar 31 2023	n/a	n/a	UK£6m
Dec 31 2022	n/a	n/a	UK£40m
Sep 30 2022	n/a	n/a	UK£49m
Jun 30 2022	UK£2m	UK£597k	UK£58m
Mar 31 2022	n/a	n/a	UK£66m
Dec 31 2021	n/a	n/a	UK£73m
Sep 30 2021	n/a	n/a	UK£64m
Jun 30 2021	UK£3m	UK£551k	UK£56m
Mar 31 2021	n/a	n/a	UK£50m
Dec 31 2020	n/a	n/a	UK£44m
Sep 30 2020	n/a	n/a	UK£39m
Jun 30 2020	UK£2m	UK£517k	UK£34m
Mar 31 2020	n/a	n/a	UK£31m
Dec 31 2019	n/a	n/a	UK£29m
Sep 30 2019	n/a	n/a	UK£30m
Jun 30 2019	UK£3m	UK£500k	UK£31m
Mar 31 2019	n/a	n/a	UK£28m
Dec 31 2018	n/a	n/a	UK£25m
Sep 30 2018	n/a	n/a	UK£30m
Jun 30 2018	UK£3m	UK£500k	UK£36m
Mar 31 2018	n/a	n/a	UK£40m
Dec 31 2017	n/a	n/a	UK£43m
Sep 30 2017	n/a	n/a	UK£35m
Jun 30 2017	UK£3m	UK£490k	UK£26m

보상 대 시장: Ian 의 총 보상 ($USD 1.31M ) UK 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 3.20M ).

보상과 수익: Ian 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Ian Page (62 yo)

22.2yrs

테뉴어

UK£1,037,000

보상

Mr. Ian D. Page has been the Chief Executive Officer and Managing Director of Dechra Pharmaceuticals Plc since November 2001 and 1998 respectively and also serves as its Executive Director since June 13, 1...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ian Page	CEO, MD & Executive Director	22.2yrs	UK£1.04m	0.36% £ 15.6m
Paul Sandland	CFO & Executive Director	4.8yrs	UK£641.00k	0.010% £ 452.7k
Patrick Meeus	Chief Scientific Officer	1.5yrs	데이터 없음	데이터 없음
Jamie Adams	Chief Information Officer	1.6yrs	데이터 없음	데이터 없음
Katy Clough	Chief People Officer	no data	데이터 없음	데이터 없음
Mike Eldred	President of North America	no data	데이터 없음	데이터 없음
Melanie Hall	Company Secretary	6.5yrs	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: DPHL 의 관리팀은 경험 ( 4.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ian Page	CEO, MD & Executive Director	26.6yrs	UK£1.04m	0.36% £ 15.6m
Paul Sandland	CFO & Executive Director	4.3yrs	UK£641.00k	0.010% £ 452.7k
Geeta Gopalan	Independent Non-Executive Director	less than a year	UK£36.00k	데이터 없음
Lawson MacArtney	Senior Independent Director	7.1yrs	UK£107.00k	0.0052% £ 227.2k
Alison Platt	Independent Non-Executive Chairman	3.8yrs	UK£207.00k	0.0033% £ 143.6k
Lisa Morrison	Designated Non-Executive Director	4.9yrs	UK£72.00k	0.0012% £ 53.3k
John Shipsey	Independent Non-Executive Director	1.6yrs	UK£73.00k	0.00053% £ 23.3k

4.3yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: DPHL 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.

Dechra Pharmaceuticals 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Less than half of directors are independent

Recent updates

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Now 21% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021)

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 21% undervalued after recent price drop

Dechra Pharmaceuticals PLC Announces Executive Changes

Less than half of directors are independent

Non-Executive Chairman recently bought UK£99k worth of stock

Upcoming dividend of UK£0.12 per share

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

Board Member recently sold UK£875k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Board Member recently sold UK£963k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

New 90-day high: UK£37.50

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

New 90-day high: UK£35.98

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령